Form 8-K BRISTOL MYERS SQUIBB CO For: Feb 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Bristol-Myers Squibb Co. (BMY) PT Raised to $67 at Goldman Sachs
February 7, 2025 7:48 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $67.00 (from $65.00) while maintaining a Buy rating.
The analyst comments "With delivery of overall solid performance from 4Q24 (top and bottom line beats vs. consensus), while share reactions on the day reflected 2025 guidance coming in modestly below expectations, we see the essential... More
